TREVENTIS™ Corporation is a biotechnology company focused on diseases associated with protein misfolding. Treventis uses a computational platform to rationally design small molecule therapeutics for protein misfolding diseases. Our lead program in Alzheimer’s Disease therapeutics is now the subject of a robust collaboration with Servier Laboratories. We have a team of chemists and biologists with leading expertise in this area and are expanding on our proprietary pipeline in Parkinson’s, ALS, an undisclosed oncology target and in rare diseases. We also have a diagnostics division for the early identification of Alzheimer’s disease.